Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.
Iomeprol was approved for medical use in the United States in November 2024.
Side effects It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium. Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.
Society and culture Iomeprol is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.
Legal status Iomeprol was approved for medical use in the United States in November 2024.
Brand names Iomeprol is sold under the brand name Iomervu.
References